Investment
Features
FeesSafety
Academy
More
Pluang+

Compare DigitalOcean Holdings Inc (DOCN) vs Heron Therapeutics Inc (HRTX) Price & Performance

DigitalOcean Holdings IncTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

DigitalOcean Holdings Inc vs Heron Therapeutics Inc — how do they compare? DigitalOcean Holdings Inc trades at $122 (market cap $15.25B), while Heron Therapeutics Inc trades at $0.32 (market cap $63.41M). The key difference: DigitalOcean Holdings Inc is far larger — about 240.5× Heron Therapeutics Inc's market cap, and DigitalOcean Holdings Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

DOCNHRTX
Market Cap
$15.25B$63.41M
Sector
TechnologyHealth
52-Week High
$181.29$1.49
52-Week Low
$29.99$0.32
Enterprise Value
$16.02B$161.31M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

DigitalOcean Holdings Inc

DigitalOcean (DOCN) trades at $124.15, up 1.57% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with 29% revenue growth driven by AI demand, and raised full-year guidance. Valuation ratios are elevated, with a P/E of 56.43 and P/S of 13.99, reflecting high growth expectations. Analyst consensus is bullish with a $173.71 price target, though net cash flow turned negative in 2025 due to investing activities.

Outlook is positive given accelerating AI-driven revenue growth and profitability, but risks include high debt levels, competitive cloud market pressures, and stretched valuations. The stock offers upside if execution continues, but investors face volatility from earnings sensitivity and macroeconomic headwinds.

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.

HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About DigitalOcean Holdings Inc

DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.

Read more on DOCN

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX